Nkarta to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:

Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat

Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

You May Also Be Interested In

• Lerøy Seafood Group ASA: Primary Insider Transaction
• MM-ARTech+ Residency Program Officially Launches in Shanghai
• Crypto News Today: AlphaPepe Presale Nears $2.5M Raised as Bitcoin Price Prediction Targets $100,000